VARIANTS WITH FC FRAGMENT HAVING AN INCREASED AFFINITY FOR FCRN AND AN INCREASED AFFINITY FOR AT LEAST ONE RECEPTOR OF THE FC FRAGMENT
Disclosed is a variant of a parent polypeptide including an Fc fragment, the variant having an increased affinity for the FcRn receptor, and an increased affinity for at least one receptor of the Fc fragment (FcR) chosen from the FcγRI (CD64), FcγRIIIa (CD16a) and FcγRIIa (CD32a) receptors, relative to that of the parent polypeptide, characterised in that it includes: (i) the four mutations 334N, 352S, 378V and 397M; and (ii) at least one mutation chosen from 434Y, 434S, 226G, P228L, P228R, 230S, 230T, 230L, 241L, 264E, 307P, 315D, 330V, 362R, 389T and 389K; the numbering being that of the EU index or the Kabat equivalent.
1 . Variant of a parent polypeptide comprising an Fc fragment, said variant having an increased affinity for the FcRn receptor, and an increased affinity for at least one Fc receptor (FcR) selected from the FcγRI (CD64), FcγRIIIa (CD16a) and FcγRIIa (CD32a), relative to that of the parent polypeptide, comprising:
(i) the four mutations 334N, 352S, 378V and 397M; and
(ii) at least one mutation selected from 434Y, 434S, 226G, P228L, P228R, 230S, 230T, 230L, 241L, 264E, 307P, 315D, 330V, 362R, 389T and 389K;
wherein the numbering is that of the EU index or equivalent in Kabat.
2 . The variant according to claim 1 , further comprising at least one mutation (iii) in the Fc fragment chosen from among Y296W, K290G, V240H, V240I, V240M, V240N, V240S, F241H, F241Y, L242A, L242F, L242G, L242H, L242I, L242K, L242P, L242S, L242T, L242V, F243L, F243S, E258G, E258I, E258R, E258M, E258Q, E258Y, V259C, V259I, V259L, T260A, T260H, T260I, T260M, T260N, T260R, T260S, T260W, V262S, V263T, V264L, V264S, V264T, V266L, S267A, S267Q, S267V, K290D, K290E, K290H, K290L, K290N, K290Q, K290R, K290S, K290Y, P291G, P291Q, P291R, R292I, R292L, E293A, E293D, E293G, E293M, E293Q, E293S, E293T, E294A, E294G, E294P, E294Q, E294R, E294T, E294V Q295I, Q295M, Y296H, S298A, S298R, Y300I, Y300V, Y300W, R301A, R301M, R301P, R301S, V302F, V302L, V302M, V302R, V302S, V303S, V303Y, S3041, V305A, V305F, V3051, V305L, V305R and V305S,
wherein the numbering is that of the EU index or equivalent in Kabat,
3 . The variant according to claim 1 , comprising:
(i) the four mutations 334N, 352S, 378V and 397M;
(ii) at least one mutation selected from 434Y, 434S, 226G, P228L, P228R, 230S, 230T, 230L, 241L, 264E, 307P, 315D, 330V, 362R, 389T and 389K; and
(iii) at least one mutation selected from K290G and Y296W,
wherein the numbering is that of the EU index or equivalent in Kabat.
4 . The variant according to claim 1 , having an increased affinity for the FcRn receptor, relative to that of the parent polypeptide, of a ratio at least equal to 2.
5 . The variant according to claim 1 , having an increased affinity for at least one Fc receptor (FcR) selected from FcγRI receptors (CD64), FcγRIIIa (CD16a) and FcγRIIα (CD32a), relative to that of the parent polypeptide, of a ratio at least equal to 2.
6 . The variant according to claim 1 , wherein the variant is produced in mammary epithelial cells of transgenic non-human mammals.
7 . The variant according to claim 1 , wherein the variant is produced in transgenic non human animals.
8 . The variant according to claim 7 , wherein the transgenic non-human animal is a transgenic goat.
9 . The variant according to claim 1 , wherein the variant the parent polypeptide comprises a parent Fc fragment which is a human Fc fragment.
10 . The variant according to claim 1 , wherein the variant is selected from an isolated Fc fragment, a sequence derived from an isolated Fc fragment, an antibody, an antibody fragment comprising an Fc fragment, and a fusion protein comprising an Fc fragment.
11 . The variant according to claim 1 , directed against an antigen selected from a tumor antigen, a viral antigen, a bacterial antigen, a fungal antigen, a toxin, a membrane or circulating cytokine, a membrane receptor.
12 . A method for treating a patient in need thereof, comprising administering an effective amount of the variant according to claim 1 to said patient.
13 . A method for treating an autoimmune or inflammatory pathology, comprising administering an effective amount of the variant according to claim 1 to a patient in need thereof.
14 . Pharmaceutical composition comprising a variant according to claim 1 , and at least one pharmaceutically acceptable excipient.
15 . Process of producing a variant of a parent polypeptide comprising an Fc fragment, said variant having increased affinity for the FcRn receptor, and increased affinity for at least one Fc receptor (FcR) selected from FcγRI receptors (CD64), FcγRIIIa (CD16a) and FcγRIIa (CD32a), relative to that of the parent polypeptide, comprising:
(i) the four mutations 334N, 352S, 378V and 397M; and
(ii) at least one mutation selected from 434Y, 434S, 226G, P228L, P228R, 230S, 230T, 230L, 241L, 264E, 307P, 315D, 330V, 362R, 389T and 389K;
wherein the numbering is that of the EU index or equivalent in Kabat, said process comprising expressing said variant in mammary epithelial cells of transgenic non-human mammals, or said process comprising expressing said variant in mammalian cells in culture.
16 . The process for producing a variant of a parent polypeptide comprising an Fc fragment according to claim 15 , wherein said variant further comprises at least one mutation (iii) in the Fc fragment chosen from among Y296W, K290G, V240H, V240I, V240M, V240N, V240S, F241H, F241Y, L242A, L242F, L242G, L242H, L242I, L242K, L242P, L242S, L242T, L242V, F243L, F243S, E258G, E258I, E258R, E258M, E258Q, E258Y, V259C, V259I, V259L, T260A, T260H, T260I, T260M, T260N, T260R, T260S, T260W, V262S, V263T, V264L, V264S, V264T, V266L, S267A, S267Q, S267V, K290D, K290E, K290H, K290L, K290N, K290Q, K290R, K290S, K290Y, P291G, P291Q, P291R, R292I, R292L, E293A, E293D, E293G, E293M, E293Q, E293S, E293T, E294A, E294G, E294P, E294Q, E294R, E294T, E294V, Q295I, Q295M, Y296H, S298A, S298R, Y300I, Y300V, Y300W, R301A, R301M, R301P, R301S, V302F, V302L, V302M, V302R, V302S, V303S, V303Y, S304T, V305A, V305F, V3051, V305L, V305R and V305S,
wherein the numbering is that of the EU index or equivalent in Kabat.
17 . The process of producing a variant of a polypeptide comprising an Fc fragment according to claim 15 , comprising the steps of:
a) preparing a DNA sequence comprising a sequence encoding the variant, a sequence encoding a mammalian casein promoter or a mammalian whey promoter, and a sequence encoding a signal peptide permitting the secretion of said variant;
b) introducing the DNA sequence obtained in a) into a non-human mammalian embryo, to obtain a transgenic non-human mammal expressing the variant encoded by said DNA sequence obtained in a) in the mammary gland; and
c) recovery of the variant in the milk produced by the transgenic nonhuman mammal obtained in b).
18 . The process for producing a variant of a polypeptide comprising an Fc fragment according to claim 15 , wherein the transgenic non-human mammal is selected from cattle, pigs, goats, sheep and rodents.
19 . The process for producing a variant of a polypeptide comprising an Fc fragment according to claim 15 , comprising the steps of:
a) preparing a DNA sequence encoding the variant;
b) introducing the DNA sequence obtained in a) into mammalian cells in transient or stable culture;
c) expression of the variant from the cells obtained in b), and
d) recovering the variant in the culture medium.
20 . DNA sequence comprising a gene encoding a variant of a parent polypeptide comprising an Fc fragment, said variant having increased affinity for the FcRn receptor, and an increased affinity for at least one Fc receptor (FcR) selected from the receptors FcγRI (CD64), FcγRII1a (CD16α) and FcγRI1a (CD32α), relative to that of the parent polypeptide, wherein said variant comprises:
(i) the four mutations 334N, 352S, 378V and 397M; and
(ii) at least one mutation selected from 434Y, 434S, 226G, P228L, P228R, 230S, 230T, 230L, 241L, 264E, 307P, 315D, 330V, 362R, 389T and 389K;
wherein the numbering is that of the EU index or equivalent in Kabat.
21 . DNA sequence comprising a gene encoding a variant of a parent polypeptide comprising an Fc fragment according to claim 20 , said variant further comprising at least one mutation (iii) in the Fc fragment selected from Y296W, K290G, V240H, V240I, V240M, V240N, V240S, F241H, F241Y, L242A, L242F, L242G, L242H, L242I, L242K, L242P, L242S, L242T, L242V, F243L, F243S, E258G, E258I, E258R, E258M, E258Q, E258Y, V259C, V259I, V259L, T260A, T260H, T260I, T260M, T260N, T260R, T260S, T260W, V262S, V263T, V264L, V264S, V264T, V266L, S267A, S267Q, S267V, K290D, K290E, K290H, K290L, K290N, K290Q, K290R, K290S, K290Y, P291G, P291Q, P291R, R292I, R292L, E293A, E293D, E293G, E293M, E293Q, E293S, E293T, E294A, E294G, E294P, E294Q, E294R, E294T, E294V, Q295I, Q295M, Y296H, S298A, S298R, Y300I, Y300V, Y300W, R301A, R301M, R301P, R301S, V302F, V302L, V302M, V302R, V302S, V303S, V303Y, S3041, V305A, V305F, V3051, V305L, V305R and V305S,
wherein the numbering is that of the EU index or equivalent in Kabat.